These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 23945733)

  • 21. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus.
    Simon JA; Lin VH; Radovich C; Bachmann GA;
    Menopause; 2013 Apr; 20(4):418-27. PubMed ID: 23096251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial.
    Constantine G; Graham S; Portman DJ; Rosen RC; Kingsberg SA
    Climacteric; 2015 Apr; 18(2):226-32. PubMed ID: 25252699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of ospemifene or lubricants on clinical signs of VVA.
    Constantine G; Graham S; Koltun WD; Kingsberg SA
    J Sex Med; 2014 Apr; 11(4):1033-1041. PubMed ID: 24443923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ospemifene: first global approval.
    Elkinson S; Yang LP
    Drugs; 2013 May; 73(6):605-12. PubMed ID: 23605694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ospemifene: A Novel Oral Therapy for Vulvovaginal Atrophy of Menopause.
    Reid RL; Black D; Derzko C; Portman D
    J Obstet Gynaecol Can; 2020 Mar; 42(3):301-303. PubMed ID: 31932249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ospemifene in the treatment of vulvovaginal atrophy.
    Barnes KN; Pearce EF; Yancey AM; Forinash AB
    Ann Pharmacother; 2014 Jun; 48(6):752-7. PubMed ID: 24615631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy.
    Bruyniks N; Biglia N; Palacios S; Mueck AO
    Climacteric; 2017 Jun; 20(3):195-204. PubMed ID: 28267367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial.
    Archer DF; Goldstein SR; Simon JA; Waldbaum AS; Sussman SA; Altomare C; Zhu J; Yoshida Y; Schaffer S; Soulban G
    Menopause; 2019 Jan; 26(6):611-621. PubMed ID: 30694917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of dyspareunia secondary to vulvovaginal atrophy.
    Fantasia HC
    Nurs Womens Health; 2014; 18(3):237-41. PubMed ID: 24939201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ospemifene use in postmenopausal women.
    Gennari L; Merlotti D; Valleggi F; Nuti R
    Expert Opin Investig Drugs; 2009 Jun; 18(6):839-49. PubMed ID: 19466874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics, pharmacodynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause.
    Bondi C; Ferrero S; Scala C; Tafi E; Racca A; Venturini PL; Leone Roberti Maggiore U
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1233-46. PubMed ID: 27476551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy.
    Nappi RE; Panay N; Bruyniks N; Castelo-Branco C; De Villiers TJ; Simon JA
    Climacteric; 2015 Apr; 18(2):233-40. PubMed ID: 25335119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical profile of women with vulvar and vaginal atrophy who are not candidates for local vaginal estrogen therapy.
    Nappi RE; Murina F; Perrone G; Villa P; Biglia N
    Minerva Ginecol; 2017 Aug; 69(4):370-380. PubMed ID: 28398023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of SERMs for treatment in postmenopausal women.
    Pinkerton JV; Thomas S
    J Steroid Biochem Mol Biol; 2014 Jul; 142():142-54. PubMed ID: 24373794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause.
    Archer DF; Simon JA; Portman DJ; Goldstein SR; Goldstein I
    Expert Rev Endocrinol Metab; 2019 Sep; 14(5):301-314. PubMed ID: 31526199
    [No Abstract]   [Full Text] [Related]  

  • 36. Ospemifene efficacy and safety data in women with vulvovaginal atrophy.
    Pup LD; Sánchez-Borrego R
    Gynecol Endocrinol; 2020 Jul; 36(7):569-577. PubMed ID: 32329400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of ospemifene on bone in postmenopausal women.
    de Villiers TJ; Altomare C; Particco M; Gambacciani M
    Climacteric; 2019 Oct; 22(5):442-447. PubMed ID: 31294631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ospemifene for the treatment of vulvar and vaginal atrophy: A meta-analysis of randomized trials. Part II: Evaluation of tolerability and safety.
    Di Donato V; Schiavi MC; Iacobelli V; D'oria O; Kontopantelis E; Simoncini T; Muzii L; Benedetti Panici P
    Maturitas; 2019 Mar; 121():93-100. PubMed ID: 30509754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast.
    Soe LH; Wurz GT; Kao CJ; Degregorio MW
    Int J Womens Health; 2013 Sep; 5():605-11. PubMed ID: 24109197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ospemifene for the treatment of vulvar and vaginal atrophy: A meta-analysis of randomized trials. Part I: Evaluation of efficacy.
    Di Donato V; Schiavi MC; Iacobelli V; D'oria O; Kontopantelis E; Simoncini T; Muzii L; Benedetti Panici P
    Maturitas; 2019 Mar; 121():86-92. PubMed ID: 30509753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.